ArticleInfectious diseases and therapy2025

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.

Samah Hayek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.